Clinical Trial Update: Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. [Phase 2]

View source ↗

Summary

Takeda-sponsored Phase 2 trial of 851B Gel for high-risk cervical human papillomavirus infection in women has been terminated, with no efficacy results reported…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• 851B Gel

Snippet

Sponsor: Takeda | Conditions: Papillomavirus Infections | Phase 2 | Status: TERMINATED